Profitability
This table compares Aadi Bioscience and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aadi Bioscience | -246.06% | -71.87% | -57.28% |
| Acerus Pharmaceuticals | -924.33% | N/A | -74.62% |
Institutional and Insider Ownership
52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aadi Bioscience | $25.07 million | 1.99 | -$65.76 million | ($2.35) | -0.86 |
| Acerus Pharmaceuticals | $2.12 million | 0.80 | -$33.82 million | ($3.57) | -0.06 |
Acerus Pharmaceuticals has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aadi Bioscience beats Acerus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Aadi Bioscience
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
